Recent Advances in Hepatocellular Carcinoma: From Diagnosis to Therapy
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: 28 October 2024 | Viewed by 146
Special Issue Editors
Interests: hepatocellular carcinoma; liver fibrosis; liver regeneration; extracellular vesicles
Special Issue Information
Dear Colleagues,
Medical technologies for hepatocellular carcinoma (HCC) have evolved remarkably in recent years, contributing to improved prognosis for patients around the world. In the area of diagnostic technology, the development of liquid biopsy such as circulating RNA and new biomarkers is currently underway, and cancer gene panel testing is being introduced on the clinical side. In the area of therapeutic techniques, the use of immuno-checkpoint inhibitors has been initiated, improving the treatment of unresectable HCC. In addition, surgical treatment includes conversion therapy with systemic chemotherapy for downstaging, and the development of minimally invasive robotic surgery. New drugs are also being tested in clinical trials one after another, and many technological developments are expected to continue in the future.
Despite these technological developments, there are still many problems that are difficult to solve. For example, there is the problem of maintaining liver function, which is always taken into consideration in the treatment of HCC. The key is how to keep or improve liver function during the treatment of HCC, but the turning point has not yet been reached. Furthermore, the cancer gene panel testing mentioned above is now being used on the clinical side, but it has not yet made a significant contribution to HCC therapy. We believe that solving these and other problems that still exist will lead to a better long-term prognosis for patients with HCC.
In this Special Issue, we invite investigators to contribute original articles, systematic reviews, mini-review articles, and non-limited articles that will stimulate the continuing efforts to develop new period to clinical applications about HCC.
Dr. Hiroyuki Abe
Dr. Toru Setsu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- systemic therapy
- immune checkpoint inhibitor
- cancer genomic profiling
- extracellular vesicles
